Background and objective: Several studies have reported an association between type 2 diabetes mellitus and hepatocellular carcinoma (HCC). Data from several retrospective studies and meta-analyses have highlighted a reduction of about 50% in the risk of developing HCC in cirrhotic patients treated with metformin for diabetes. The aim of this study was to evaluate the different outcomes of patients who received or did not receive metformin during treatment with sorafenib.Methods: We analyzed 93 patients consecutively treated with sorafenib. Forty-two (45.2%) patients were diabetic, of whom 31 were on metformin. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with the log-rank test.Results: The concomitant use of sorafenib and metformin was associated with a median PFS of 2.6 months (95% CI 1.9-3.3) compared to 5.0 months (95% CI 2.5-8.2) for patients receiving sorafenib alone (p = 0.029). The median OS of patients treated with the combination was 10.4 months (95% CI 3.9-14.4) compared to 15.1 months (95% CI 11.7-17.8) for those who were not given metformin (p = 0.014).Conclusions: Our findings could be the result of increased tumor aggressiveness and resistance to sorafenib in metformin-treated patients.

Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib / Casadei Gardini, Andrea; Marisi, Giorgia; Scarpi, Emanuela; Scartozzi, Mario; Faloppi, Luca; Silvestris, Nicola; Masi, Gianluca; Vivaldi, Caterina; Brunetti, Oronzo; Tamberi, Stefano; Foschi, Francesco Giuseppe; Tamburini, Emiliano; Tenti, Elena; Ricca Rosellini, Salvatore; Ulivi, Paola; Cascinu, Stefano; Nanni, Oriana; Frassineti, Giovanni Luca. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 16:(2015), pp. 2719-2725. [10.1517/14656566.2015.1102887]

Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib

Casadei Gardini, Andrea;Scartozzi, Mario;Tamberi, Stefano;Cascinu, Stefano;
2015

Abstract

Background and objective: Several studies have reported an association between type 2 diabetes mellitus and hepatocellular carcinoma (HCC). Data from several retrospective studies and meta-analyses have highlighted a reduction of about 50% in the risk of developing HCC in cirrhotic patients treated with metformin for diabetes. The aim of this study was to evaluate the different outcomes of patients who received or did not receive metformin during treatment with sorafenib.Methods: We analyzed 93 patients consecutively treated with sorafenib. Forty-two (45.2%) patients were diabetic, of whom 31 were on metformin. Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with the log-rank test.Results: The concomitant use of sorafenib and metformin was associated with a median PFS of 2.6 months (95% CI 1.9-3.3) compared to 5.0 months (95% CI 2.5-8.2) for patients receiving sorafenib alone (p = 0.029). The median OS of patients treated with the combination was 10.4 months (95% CI 3.9-14.4) compared to 15.1 months (95% CI 11.7-17.8) for those who were not given metformin (p = 0.014).Conclusions: Our findings could be the result of increased tumor aggressiveness and resistance to sorafenib in metformin-treated patients.
29-ott-2015
16
2719
2725
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib / Casadei Gardini, Andrea; Marisi, Giorgia; Scarpi, Emanuela; Scartozzi, Mario; Faloppi, Luca; Silvestris, Nicola; Masi, Gianluca; Vivaldi, Caterina; Brunetti, Oronzo; Tamberi, Stefano; Foschi, Francesco Giuseppe; Tamburini, Emiliano; Tenti, Elena; Ricca Rosellini, Salvatore; Ulivi, Paola; Cascinu, Stefano; Nanni, Oriana; Frassineti, Giovanni Luca. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 16:(2015), pp. 2719-2725. [10.1517/14656566.2015.1102887]
Casadei Gardini, Andrea; Marisi, Giorgia; Scarpi, Emanuela; Scartozzi, Mario; Faloppi, Luca; Silvestris, Nicola; Masi, Gianluca; Vivaldi, Caterina; Brunetti, Oronzo; Tamberi, Stefano; Foschi, Francesco Giuseppe; Tamburini, Emiliano; Tenti, Elena; Ricca Rosellini, Salvatore; Ulivi, Paola; Cascinu, Stefano; Nanni, Oriana; Frassineti, Giovanni Luca
File in questo prodotto:
File Dimensione Formato  
casadeigardini2015.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 570.12 kB
Formato Adobe PDF
570.12 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177519
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 48
social impact